Main Page: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:<span style="display: none"></span>}} | {{DISPLAYTITLE:<span style="display: none"></span>}} | ||
__NOTOC__ | __NOTOC__ | ||
<span class="mwt-editable mwt-comment" id="R1766923378676" " draggable="false" contenteditable="true">Hides title of Main Page | |||
<div style="text-align:center"> | <div style="text-align:center"> | ||
<div style="text-align:center">< | <h1>Welcome to Neoplasm.org</h1></div> | ||
<div style="text-align: center;" ><p>'''Neoplasm.org''' is a collaborative, open-access knowledge base dedicated to the rapid dissemination of oncology clinical trial results and evidence-based treatment regimens.</p><p>Modeled after the collaborative spirit of the medical community, our mission is to translate complex research into actionable clinical insights—free of charge and accessible to everyone, from oncologists and researchers to students and patients.</p></div> | |||
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;" | {| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;" | ||
|- | |- | ||
| | |||
| | |||
| | |||
| | |||
| | |} | ||
{| class="wikitable" style="text-align: center; margin-left: auto; margin-right: auto; font-size: 125%; font-weight: bold; width: 100%; height: 93px;" | |||
|- style="height: 65px;" | |||
| style="width: 10%; font-size: 125%; background-color: rgb(8, 81, 156); height: 65px;" | <span style="color:white;"><span style="color: black;" >[[Guidelines]]</span></span> | |||
| style="width: 10%; font-size: 125%; background-color: rgb(8, 81, 156); height: 65px;" | [[#solidtumors|<span style="color:white;">Solid Tumors</span>]] | |||
|- style="height: 28px;" | |||
| style="width: 10%; height: 28px;" | | |||
| style="width: 10%; height: 28px;" | | |||
|} | |} | ||
<span id="solidtumors"></span> | <span id="solidtumors"></span> | ||
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | {| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | ||
! | ! style="color:white; font-size:150%; background-color:#08519c" colspan="4" align="center" | '''Solid Tumors''' | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Breast Oncology''' | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Early breast cancer (EBC)''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Early breast cancer|EBC, NOS]] | | style="background-color:#eff3ff" | [[Early breast cancer|EBC, NOS]] | ||
|style="background-color:#eff3ff"|[[Early breast cancer, HR-positive|HR-positive EBC]] | | style="background-color:#eff3ff" | [[Early breast cancer, HR-positive|HR-positive EBC]] | ||
|style="background-color:#eff3ff"|[[Early breast cancer, HER2-positive|HER2-positive EBC]] | | style="background-color:#eff3ff" | [[Early breast cancer, HER2-positive|HER2-positive EBC]] | ||
|style="background-color:#eff3ff"|[[Early breast cancer, HER2-low|HER2-low EBC]] | | style="background-color:#eff3ff" | [[Early breast cancer, HER2-low|HER2-low EBC]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Early breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive EBC]] | | style="background-color:#eff3ff" | [[Early breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive EBC]] | ||
|style="background-color:#eff3ff"|[[Early breast cancer, triple negative|Early triple-negative breast cancer (eTNBC)]] | | style="background-color:#eff3ff" | [[Early breast cancer, triple negative|Early triple-negative breast cancer (eTNBC)]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Metastatic breast cancer (MBC)''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Metastatic breast cancer|MBC, NOS]] | | style="background-color:#eff3ff" | [[Metastatic breast cancer|MBC, NOS]] | ||
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HR-positive|HR-positive MBC]] | | style="background-color:#eff3ff" | [[Metastatic breast cancer, HR-positive|HR-positive MBC]] | ||
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HER2-positive|HER2-positive MBC]] | | style="background-color:#eff3ff" | [[Metastatic breast cancer, HER2-positive|HER2-positive MBC]] | ||
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HER2-low|HER2-low MBC]] | | style="background-color:#eff3ff" | [[Metastatic breast cancer, HER2-low|HER2-low MBC]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive MBC]] | | style="background-color:#eff3ff" | [[Metastatic breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive MBC]] | ||
|style="background-color:#eff3ff"|[[Metastatic breast cancer, triple negative|Metastatic triple-negative breast cancer (mTNBC)]] | | style="background-color:#eff3ff" | [[Metastatic breast cancer, triple negative|Metastatic triple-negative breast cancer (mTNBC)]] | ||
|style="background-color:#eff3ff"|[[Breast cancer, CNS metastases|CNS metastases]] | | style="background-color:#eff3ff" | [[Breast cancer, CNS metastases|CNS metastases]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Breast cancer with molecular alterations''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Test|Testfdasfjifojifjo]] | | style="background-color:#eff3ff" | [[Test|Testfdasfjifojifjo]] | ||
|style="background-color:#eff3ff"|[[Metastatic breast cancer, PI3K pathway-altered|PI3K pathway-altered Breast cancer]] | | style="background-color:#eff3ff" | [[Metastatic breast cancer, PI3K pathway-altered|PI3K pathway-altered Breast cancer]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Dermatologic Oncology''' | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Melanoma''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Melanoma|Melanoma, NOS]] | | style="background-color:#eff3ff" | [[Melanoma|Melanoma, NOS]] | ||
|style="background-color:#eff3ff"|[[Melanoma,_BRAF-mutated|BRAF-mutated Melanoma]] | | style="background-color:#eff3ff" | [[Melanoma,_BRAF-mutated|BRAF-mutated Melanoma]] | ||
|style="background-color:#eff3ff"|[[Melanoma,_KIT-mutated|KIT-mutated Melanoma]] | | style="background-color:#eff3ff" | [[Melanoma,_KIT-mutated|KIT-mutated Melanoma]] | ||
|style="background-color:#eff3ff"|[[Melanoma,_NRAS-mutated|NRAS-mutated Melanoma]] | | style="background-color:#eff3ff" | [[Melanoma,_NRAS-mutated|NRAS-mutated Melanoma]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Uveal melanoma]] | | style="background-color:#eff3ff" | [[Uveal melanoma]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Non-melanoma skin cancer (NMSC)''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Cutaneous basal cell carcinoma | Cutaneous BCC]] | | style="background-color:#eff3ff" | [[Cutaneous basal cell carcinoma | Cutaneous BCC]] | ||
|style="background-color:#eff3ff"|[[Cutaneous squamous cell carcinoma | Cutaneous SCC]] | | style="background-color:#eff3ff" | [[Cutaneous squamous cell carcinoma | Cutaneous SCC]] | ||
|style="background-color:#eff3ff"|[[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]] | | style="background-color:#eff3ff" | [[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Endocrine Oncology''' | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Other endocrine cancers''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Adrenocortical carcinoma]] | | style="background-color:#eff3ff" | [[Adrenocortical carcinoma]] | ||
|style="background-color:#eff3ff"|[[Neuroendocrine tumor|Neuroendocrine tumor (NET)]] | | style="background-color:#eff3ff" | [[Neuroendocrine tumor|Neuroendocrine tumor (NET)]] | ||
|style="background-color:#eff3ff"|[[Neuroendocrine carcinoma|Neuroendocrine carcinoma (NEC)]] | | style="background-color:#eff3ff" | [[Neuroendocrine carcinoma|Neuroendocrine carcinoma (NEC)]] | ||
|style="background-color:#eff3ff"|[[Pancreatic NET]] | | style="background-color:#eff3ff" | [[Pancreatic NET]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Pheochromocytoma]] | | style="background-color:#eff3ff" | [[Pheochromocytoma]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Thyroid cancer without molecular alterations''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Thyroid cancer|Thyroid cancer, NOS]] | | style="background-color:#eff3ff" | [[Thyroid cancer|Thyroid cancer, NOS]] | ||
|style="background-color:#eff3ff"|[[Thyroid cancer, anaplastic|Anaplastic thyroid cancer (ATC)]] | | style="background-color:#eff3ff" | [[Thyroid cancer, anaplastic|Anaplastic thyroid cancer (ATC)]] | ||
|style="background-color:#eff3ff"|[[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]] | | style="background-color:#eff3ff" | [[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]] | ||
|style="background-color:#eff3ff"|[[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]] | | style="background-color:#eff3ff" | [[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Thyroid cancer with molecular alterations''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Thyroid_cancer,_BRAF-mutated|BRAF-mutated Thyroid cancer]] | | style="background-color:#eff3ff" | [[Thyroid_cancer,_BRAF-mutated|BRAF-mutated Thyroid cancer]] | ||
|style="background-color:#eff3ff"|[[Thyroid_cancer,_RET-positive|RET-positive Thyroid cancer]] | | style="background-color:#eff3ff" | [[Thyroid_cancer,_RET-positive|RET-positive Thyroid cancer]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Gastrointestinal Oncology''' | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Upper GI tract''' | ||
|- | |- | ||
|style="width: 25%; background-color:#eff3ff"|[[Esophageal cancer|Esophageal cancer, NOS]] | | style="width: 25%; background-color:#eff3ff" | [[Esophageal cancer|Esophageal cancer, NOS]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Esophageal adenocarcinoma]] | | style="width: 25%; background-color:#eff3ff" | [[Esophageal adenocarcinoma]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Esophageal squamous cell carcinoma|Esophageal squamous cell carcinoma (ESCC)]] | | style="width: 25%; background-color:#eff3ff" | [[Esophageal squamous cell carcinoma|Esophageal squamous cell carcinoma (ESCC)]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Gastric cancer|Gastric cancer, NOS]] | | style="width: 25%; background-color:#eff3ff" | [[Gastric cancer|Gastric cancer, NOS]] | ||
|- | |- | ||
|style="width: 25%; background-color:#eff3ff"|[[Gastric cancer, HER2-positive|HER2-positive gastric cancer]] | | style="width: 25%; background-color:#eff3ff" | [[Gastric cancer, HER2-positive|HER2-positive gastric cancer]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Lower GI tract''' | ||
|- | |- | ||
|style="width: 25%; background-color:#eff3ff"|[[Anal cancer]] | | style="width: 25%; background-color:#eff3ff" | [[Anal cancer]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Appendiceal tumor]] | | style="width: 25%; background-color:#eff3ff" | [[Appendiceal tumor]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Colon cancer|Colon cancer, NOS]] | | style="width: 25%; background-color:#eff3ff" | [[Colon cancer|Colon cancer, NOS]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Colon cancer, RAS wild-type|RAS wild-type colon cancer]] | | style="width: 25%; background-color:#eff3ff" | [[Colon cancer, RAS wild-type|RAS wild-type colon cancer]] | ||
|- | |- | ||
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer|Colorectal cancer (CRC), NOS]] | | style="width: 25%; background-color:#eff3ff" | [[Colorectal cancer|Colorectal cancer (CRC), NOS]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, BRAF-mutated|BRAF-mutated CRC]] | | style="width: 25%; background-color:#eff3ff" | [[Colorectal cancer, BRAF-mutated|BRAF-mutated CRC]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, HER2-positive|HER2-positive CRC]] | | style="width: 25%; background-color:#eff3ff" | [[Colorectal cancer, HER2-positive|HER2-positive CRC]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, MSI-H or dMMR|MSI-H or dMMR CRC]] | | style="width: 25%; background-color:#eff3ff" | [[Colorectal cancer, MSI-H or dMMR|MSI-H or dMMR CRC]] | ||
|- | |- | ||
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, RAS wild-type|RAS wild-type CRC]] | | style="width: 25%; background-color:#eff3ff" | [[Colorectal cancer, RAS wild-type|RAS wild-type CRC]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Rectal cancer]] | | style="width: 25%; background-color:#eff3ff" | [[Rectal cancer]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Small bowel adenocarcinoma]] | | style="width: 25%; background-color:#eff3ff" | [[Small bowel adenocarcinoma]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Hepatobiliary cancer''' | ||
|- | |- | ||
|style="width: 25%; background-color:#eff3ff"|[[Biliary tract cancer]] | | style="width: 25%; background-color:#eff3ff" | [[Biliary tract cancer]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Cholangiocarcinoma]] | | style="width: 25%; background-color:#eff3ff" | [[Cholangiocarcinoma]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Gallbladder cancer]] | | style="width: 25%; background-color:#eff3ff" | [[Gallbladder cancer]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Hepatocellular carcinoma|Hepatocellular carcinoma (HCC)]] | | style="width: 25%; background-color:#eff3ff" | [[Hepatocellular carcinoma|Hepatocellular carcinoma (HCC)]] | ||
|- | |- | ||
|style="width: 25%; background-color:#eff3ff"|[[Periampullary adenocarcinoma]] | | style="width: 25%; background-color:#eff3ff" | [[Periampullary adenocarcinoma]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Pancreatic cancer''' | ||
|- | |- | ||
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer|Pancreatic adenocarcinoma, NOS]] | | style="width: 25%; background-color:#eff3ff" | [[Pancreatic cancer|Pancreatic adenocarcinoma, NOS]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer, BRCA-mutated|BRCA-mutated Pancreatic adenocarcinoma]] | | style="width: 25%; background-color:#eff3ff" | [[Pancreatic cancer, BRCA-mutated|BRCA-mutated Pancreatic adenocarcinoma]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer, NRG1-positive|NRG1-positive Pancreatic adenocarcinoma]] | | style="width: 25%; background-color:#eff3ff" | [[Pancreatic cancer, NRG1-positive|NRG1-positive Pancreatic adenocarcinoma]] | ||
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic NET]] | | style="width: 25%; background-color:#eff3ff" | [[Pancreatic NET]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Genitourinary Oncology''' | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Kidney cancer''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Renal cell carcinoma|Renal cell carcinoma (RCC), NOS]] | | style="background-color:#eff3ff" | [[Renal cell carcinoma|Renal cell carcinoma (RCC), NOS]] | ||
|style="background-color:#eff3ff"|[[Clear cell renal cell carcinoma|Clear cell RCC (ccRCC)]] | | style="background-color:#eff3ff" | [[Clear cell renal cell carcinoma|Clear cell RCC (ccRCC)]] | ||
|style="background-color:#eff3ff"|[[Non-clear cell renal cell carcinoma|Non-clear cell RCC (nccRCC)]] | | style="background-color:#eff3ff" | [[Non-clear cell renal cell carcinoma|Non-clear cell RCC (nccRCC)]] | ||
|style="background-color:#eff3ff"|[[Papillary renal cell carcinoma|Papillary RCC]] | | style="background-color:#eff3ff" | [[Papillary renal cell carcinoma|Papillary RCC]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Sarcomatoid renal cell carcinoma|Sarcomatoid RCC]] | | style="background-color:#eff3ff" | [[Sarcomatoid renal cell carcinoma|Sarcomatoid RCC]] | ||
|style="background-color:#eff3ff"|[[Renal_cell_carcinoma,_VHL-associated|VHL-associated RCC]] | | style="background-color:#eff3ff" | [[Renal_cell_carcinoma,_VHL-associated|VHL-associated RCC]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Male genital tract''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Penile cancer]] | | style="background-color:#eff3ff" | [[Penile cancer]] | ||
|style="background-color:#eff3ff"|[[Prostate cancer|Prostate cancer, NOS]] | | style="background-color:#eff3ff" | [[Prostate cancer|Prostate cancer, NOS]] | ||
|style="background-color:#eff3ff"|[[Prostate cancer, HRD-positive]] | | style="background-color:#eff3ff" | [[Prostate cancer, HRD-positive]] | ||
|style="background-color:#eff3ff"|[[Testicular cancer]] | | style="background-color:#eff3ff" | [[Testicular cancer]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Urinary tract cancer''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Urothelial carcinoma|Urothelial carcinoma, NOS]] | | style="background-color:#eff3ff" | [[Urothelial carcinoma|Urothelial carcinoma, NOS]] | ||
|style="background-color:#eff3ff"|[[Bladder cancer]] | | style="background-color:#eff3ff" | [[Bladder cancer]] | ||
|style="background-color:#eff3ff"|[[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]] | | style="background-color:#eff3ff" | [[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Gynecologic Oncology''' | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Ovarian cancer''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Ovarian cancer|High-grade serous ovarian cancer (HGSOC)]] | | style="background-color:#eff3ff" | [[Ovarian cancer|High-grade serous ovarian cancer (HGSOC)]] | ||
|style="background-color:#eff3ff"|[[Low-grade serous ovarian cancer|Low-grade serous ovarian cancer (LGSOC)]] | | style="background-color:#eff3ff" | [[Low-grade serous ovarian cancer|Low-grade serous ovarian cancer (LGSOC)]] | ||
|style="background-color:#eff3ff"|[[Ovarian cancer, BRCA-mutated]] | | style="background-color:#eff3ff" | [[Ovarian cancer, BRCA-mutated]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Other gynecologic cancer''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Cervical cancer]] | | style="background-color:#eff3ff" | [[Cervical cancer]] | ||
|style="background-color:#eff3ff"|[[Endometrial cancer]] | | style="background-color:#eff3ff" | [[Endometrial cancer]] | ||
|style="background-color:#eff3ff"|[[Gestational trophoblastic neoplasia]] | | style="background-color:#eff3ff" | [[Gestational trophoblastic neoplasia]] | ||
|style="background-color:#eff3ff"|[[Vulvar cancer]] | | style="background-color:#eff3ff" | [[Vulvar cancer]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Head & Neck Oncology''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Head and neck cancer]] | | style="background-color:#eff3ff" | [[Head and neck cancer]] | ||
|style="background-color:#eff3ff"|[[Nasopharyngeal carcinoma|Nasopharyngeal carcinoma (NPC)]] | | style="background-color:#eff3ff" | [[Nasopharyngeal carcinoma|Nasopharyngeal carcinoma (NPC)]] | ||
|style="background-color:#eff3ff"|[[Oropharyngeal_cancer,_HPV-positive|HPV+ Oropharyngeal cancer]] | | style="background-color:#eff3ff" | [[Oropharyngeal_cancer,_HPV-positive|HPV+ Oropharyngeal cancer]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Mesothelioma''' | ||
|- | |- | ||
| | | style="background-color:#eff3ff" colspan="2" | [[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]] | ||
| | | style="background-color:#eff3ff" colspan="2" | [[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Neuro-Oncology''' | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Primary central nervous system (CNS) malignancies''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Anaplastic glioma]] | | style="background-color:#eff3ff" | [[Anaplastic glioma]] | ||
|style="background-color:#eff3ff"|[[Craniopharyngioma]] | | style="background-color:#eff3ff" | [[Craniopharyngioma]] | ||
|style="background-color:#eff3ff"|[[Diffuse midline glioma]] <span style="color: red"><small>New</small></span> | | style="background-color:#eff3ff" | [[Diffuse midline glioma]] <span style="color: red"><small>New</small></span> | ||
|style="background-color:#eff3ff"|[[Glioblastoma|Glioblastoma (GBM)]] | | style="background-color:#eff3ff" | [[Glioblastoma|Glioblastoma (GBM)]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Low-grade glioma]] | | style="background-color:#eff3ff" | [[Low-grade glioma]] | ||
|style="background-color:#eff3ff"|[[Meningioma]] | | style="background-color:#eff3ff" | [[Meningioma]] | ||
|style="background-color:#eff3ff"|[[Subependymal giant cell astrocytoma|Subependymal giant cell astrocytoma (SEGA)]] | | style="background-color:#eff3ff" | [[Subependymal giant cell astrocytoma|Subependymal giant cell astrocytoma (SEGA)]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Secondary CNS malignancies''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[CNS carcinoma]] | | style="background-color:#eff3ff" | [[CNS carcinoma]] | ||
|style="background-color:#eff3ff"|[[CNS leukemia]] | | style="background-color:#eff3ff" | [[CNS leukemia]] | ||
|style="background-color:#eff3ff"|[[CNS lymphoma]] | | style="background-color:#eff3ff" | [[CNS lymphoma]] | ||
|style="background-color:#eff3ff"|[[CNS melanoma]] | | style="background-color:#eff3ff" | [[CNS melanoma]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Sarcoma''' | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Bone sarcoma''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Bone sarcoma|Bone sarcoma, NOS]] | | style="background-color:#eff3ff" | [[Bone sarcoma|Bone sarcoma, NOS]] | ||
|style="background-color:#eff3ff"|[[Ewing sarcoma]] | | style="background-color:#eff3ff" | [[Ewing sarcoma]] | ||
|style="background-color:#eff3ff"|[[Giant-cell tumor of bone]] | | style="background-color:#eff3ff" | [[Giant-cell tumor of bone]] | ||
|style="background-color:#eff3ff"|[[Osteosarcoma]] | | style="background-color:#eff3ff" | [[Osteosarcoma]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Soft tissue sarcoma''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Soft tissue sarcoma|Soft tissue sarcoma (STS), NOS]] | | style="background-color:#eff3ff" | [[Soft tissue sarcoma|Soft tissue sarcoma (STS), NOS]] | ||
|style="background-color:#eff3ff"|[[Alveolar soft part sarcoma|Alveolar soft part sarcoma (ASPS)]] | | style="background-color:#eff3ff" | [[Alveolar soft part sarcoma|Alveolar soft part sarcoma (ASPS)]] | ||
|style="background-color:#eff3ff"|[[Dermatofibrosarcoma protuberans]] | | style="background-color:#eff3ff" | [[Dermatofibrosarcoma protuberans]] | ||
|style="background-color:#eff3ff"|[[Desmoid tumor]] | | style="background-color:#eff3ff" | [[Desmoid tumor]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Epithelioid sarcoma]] | | style="background-color:#eff3ff" | [[Epithelioid sarcoma]] | ||
|style="background-color:#eff3ff"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]] | | style="background-color:#eff3ff" | [[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]] | ||
|style="background-color:#eff3ff"|[[Inflammatory myofibroblastic tumor|Inflammatory myofibroblastic tumor (IMT)]] | | style="background-color:#eff3ff" | [[Inflammatory myofibroblastic tumor|Inflammatory myofibroblastic tumor (IMT)]] | ||
|style="background-color:#eff3ff"|[[Leiomyosarcoma|Leiomyosarcoma (LMS)]] | | style="background-color:#eff3ff" | [[Leiomyosarcoma|Leiomyosarcoma (LMS)]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Liposarcoma]] | | style="background-color:#eff3ff" | [[Liposarcoma]] | ||
|style="background-color:#eff3ff"|[[PEComa]] | | style="background-color:#eff3ff" | [[PEComa]] | ||
|style="background-color:#eff3ff"|[[Rhabdomyosarcoma|Rhabdomyosarcoma (RMS)]] | | style="background-color:#eff3ff" | [[Rhabdomyosarcoma|Rhabdomyosarcoma (RMS)]] | ||
|style="background-color:#eff3ff"|[[Tenosynovial giant cell tumor|Tenosynovial giant cell tumor (TGCT)]] | | style="background-color:#eff3ff" | [[Tenosynovial giant cell tumor|Tenosynovial giant cell tumor (TGCT)]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Vascular sarcoma''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Vascular sarcoma|Vascular sarcoma, NOS]] | | style="background-color:#eff3ff" | [[Vascular sarcoma|Vascular sarcoma, NOS]] | ||
|style="background-color:#eff3ff"|[[Angiosarcoma]] | | style="background-color:#eff3ff" | [[Angiosarcoma]] | ||
|style="background-color:#eff3ff"|[[Kaposi sarcoma|Kaposi sarcoma (KS)]] | | style="background-color:#eff3ff" | [[Kaposi sarcoma|Kaposi sarcoma (KS)]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Thoracic Oncology''' | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Non-small cell lung cancer (NSCLC) without driver alterations''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Non-small cell lung cancer |NSCLC, NOS]] | | style="background-color:#eff3ff" | [[Non-small cell lung cancer |NSCLC, NOS]] | ||
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, nonsquamous|Nonsquamous NSCLC]] | | style="background-color:#eff3ff" | [[Non-small cell lung cancer, nonsquamous|Nonsquamous NSCLC]] | ||
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, squamous|Squamous NSCLC]] | | style="background-color:#eff3ff" | [[Non-small cell lung cancer, squamous|Squamous NSCLC]] | ||
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, PD-L1-positive|PD-L1-positive NSCLC]] | | style="background-color:#eff3ff" | [[Non-small cell lung cancer, PD-L1-positive|PD-L1-positive NSCLC]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_CNS_metastases|CNS metastases]] | | style="background-color:#eff3ff" | [[Non-small_cell_lung_cancer,_CNS_metastases|CNS metastases]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''NSCLC with driver alterations''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_ALK-positive|ALK-positive NSCLC]] | | style="background-color:#eff3ff" | [[Non-small_cell_lung_cancer,_ALK-positive|ALK-positive NSCLC]] | ||
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_BRAF-mutated|BRAF-mutated NSCLC]] | | style="background-color:#eff3ff" | [[Non-small_cell_lung_cancer,_BRAF-mutated|BRAF-mutated NSCLC]] | ||
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, c-Met-positive|c-Met-positive NSCLC]] | | style="background-color:#eff3ff" | [[Non-small cell lung cancer, c-Met-positive|c-Met-positive NSCLC]] | ||
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_EGFR-mutated|EGFR-mutated NSCLC]] | | style="background-color:#eff3ff" | [[Non-small_cell_lung_cancer,_EGFR-mutated|EGFR-mutated NSCLC]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_HER2-mutated|HER2-mutated NSCLC]] | | style="background-color:#eff3ff" | [[Non-small_cell_lung_cancer,_HER2-mutated|HER2-mutated NSCLC]] | ||
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_KRAS-mutated|KRAS-mutated NSCLC]] | | style="background-color:#eff3ff" | [[Non-small_cell_lung_cancer,_KRAS-mutated|KRAS-mutated NSCLC]] | ||
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, MET-mutated|MET-mutated NSCLC]] | | style="background-color:#eff3ff" | [[Non-small cell lung cancer, MET-mutated|MET-mutated NSCLC]] | ||
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, NRG1-positive|NRG1-positive NSCLC]] | | style="background-color:#eff3ff" | [[Non-small cell lung cancer, NRG1-positive|NRG1-positive NSCLC]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, RET-positive|RET-positive NSCLC]] | | style="background-color:#eff3ff" | [[Non-small cell lung cancer, RET-positive|RET-positive NSCLC]] | ||
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_ROS1-positive|ROS1-positive NSCLC]] | | style="background-color:#eff3ff" | [[Non-small_cell_lung_cancer,_ROS1-positive|ROS1-positive NSCLC]] | ||
|- | |- | ||
| | | style="background-color:#bdd7e7" colspan="4" | '''Other thoracic cancer''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]] | | style="background-color:#eff3ff" | [[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]] | ||
|style="background-color:#eff3ff"|[[Small cell lung cancer |Small cell lung cancer (SCLC)]] | | style="background-color:#eff3ff" | [[Small cell lung cancer |Small cell lung cancer (SCLC)]] | ||
|style="background-color:#eff3ff"|[[Thymoma]] | | style="background-color:#eff3ff" | [[Thymoma]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#6baed6" colspan="4" | '''Site-agnostic''' | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[BRAF]] | | style="background-color:#eff3ff" | [[BRAF]] | ||
|style="background-color:#eff3ff"|[[EGFR]] | | style="background-color:#eff3ff" | [[EGFR]] | ||
|style="background-color:#eff3ff"|[[ERBB2 (HER2)]] | | style="background-color:#eff3ff" | [[ERBB2 (HER2)]] | ||
|style="background-color:#eff3ff"|[[ERBB3 (HER3)]] | | style="background-color:#eff3ff" | [[ERBB3 (HER3)]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[MSI-H or dMMR]] | | style="background-color:#eff3ff" | [[MSI-H or dMMR]] | ||
|style="background-color:#eff3ff"|[[NTRK]] | | style="background-color:#eff3ff" | [[NTRK]] | ||
|style="background-color:#eff3ff"|[[RET]] | | style="background-color:#eff3ff" | [[RET]] | ||
|style="background-color:#eff3ff"|[[SMO or PTCH-1 (Hedgehog)]] | | style="background-color:#eff3ff" | [[SMO or PTCH-1 (Hedgehog)]] | ||
|- | |- | ||
|style="background-color:#eff3ff"|[[TMB-H]] | | style="background-color:#eff3ff" | [[TMB-H]] | ||
|style="background-color:#eff3ff"|[[Carcinoma of unknown primary|Carcinoma of unknown primary (CUP)]] | | style="background-color:#eff3ff" | [[Carcinoma of unknown primary|Carcinoma of unknown primary (CUP)]] | ||
|- | |- | ||
|} | |} | ||
<span id="malignantheme"></span> | <span id="malignantheme"></span> | ||
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | {| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | ||
! | ! style="color:white; font-size:150%; background-color:#cf0001" colspan="4" align="center" | '''Malignant Hematology''' | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#fc9272" colspan="4" | '''Acute leukemias''' | ||
|- | |- | ||
|style="width: 25%; background-color:#fee0d2"|[[Acute leukemia, KMT2A-rearranged]] | | style="width: 25%; background-color:#fee0d2" | [[Acute leukemia, KMT2A-rearranged]] | ||
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]] | | style="width: 25%; background-color:#fee0d2" | [[Acute myeloid leukemia | Acute myeloid leukemia (AML)]] | ||
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, FLT3-positive | AML, FLT3-positive]] | | style="width: 25%; background-color:#fee0d2" | [[Acute myeloid leukemia, FLT3-positive | AML, FLT3-positive]] | ||
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, IDH-mutated | AML, IDH-mutated]] | | style="width: 25%; background-color:#fee0d2" | [[Acute myeloid leukemia, IDH-mutated | AML, IDH-mutated]] | ||
|- | |- | ||
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, NPM1-mutated | AML, NPM1-mutated]] | | style="width: 25%; background-color:#fee0d2" | [[Acute myeloid leukemia, NPM1-mutated | AML, NPM1-mutated]] | ||
|style="width: 25%; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]] | | style="width: 25%; background-color:#fee0d2" | [[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]] | ||
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]] | | style="background-color:#fee0d2" | [[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]] | ||
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia, Ph-positive | B-ALL, Ph+]] | | style="background-color:#fee0d2" | [[B-cell acute lymphoblastic leukemia, Ph-positive | B-ALL, Ph+]] | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]] | | style="background-color:#fee0d2" | [[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]] | ||
|style="background-color:#fee0d2"|[[Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm (BPDCN)]] | | style="background-color:#fee0d2" | [[Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm (BPDCN)]] | ||
|style="background-color:#fee0d2"|[[CNS leukemia]] | | style="background-color:#fee0d2" | [[CNS leukemia]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#fc9272" colspan="4" | '''Myeloproliferative neoplasms and myelodysplastic syndromes''' | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Chronic myeloid leukemia | Chronic myeloid leukemia (CML)]] | | style="background-color:#fee0d2" | [[Chronic myeloid leukemia | Chronic myeloid leukemia (CML)]] | ||
|style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]] | | style="background-color:#fee0d2" | [[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]] | ||
|style="background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]] | | style="background-color:#fee0d2" | [[Essential thrombocythemia | Essential thrombocythemia (ET)]] | ||
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]] | | style="background-color:#fee0d2" | [[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]] | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]] | | style="background-color:#fee0d2" | [[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]] | ||
|style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis (PMF/SMF)]] | | style="background-color:#fee0d2" | [[Myelofibrosis | Primary & secondary myelofibrosis (PMF/SMF)]] | ||
|style="background-color:#fee0d2"|[[Myeloproliferative neoplasm, accelerated phase|Myeloproliferative neoplasm, accelerated phase (MPN-AP)]] <span style="color: red"><small>New</small></span> | | style="background-color:#fee0d2" | [[Myeloproliferative neoplasm, accelerated phase|Myeloproliferative neoplasm, accelerated phase (MPN-AP)]] <span style="color: red"><small>New</small></span> | ||
|style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]] | | style="background-color:#fee0d2" | [[Polycythemia vera | Polycythemia vera (PV)]] | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Systemic mastocytosis]] | | style="background-color:#fee0d2" | [[Systemic mastocytosis]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#fc9272" colspan="4" | '''Aggressive lymphomas''' | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]] | | style="background-color:#fee0d2" | [[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]] | ||
|style="background-color:#fee0d2"|[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]] | | style="background-color:#fee0d2" | [[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]] | ||
|style="background-color:#fee0d2"|[[CNS lymphoma]] | | style="background-color:#fee0d2" | [[CNS lymphoma]] | ||
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]] | | style="background-color:#fee0d2" | [[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]] | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma, gastric|Gastric DLBCL]] <span style="color: red"><small>New</small></span> | | style="background-color:#fee0d2" | [[Diffuse large B-cell lymphoma, gastric|Gastric DLBCL]] <span style="color: red"><small>New</small></span> | ||
|style="background-color:#fee0d2"|[[High-grade B-cell lymphoma|High-grade B-cell lymphoma (HGBL)]] | | style="background-color:#fee0d2" | [[High-grade B-cell lymphoma|High-grade B-cell lymphoma (HGBL)]] | ||
|style="background-color:#fee0d2"|[[HIV-associated lymphoma]] | | style="background-color:#fee0d2" | [[HIV-associated lymphoma]] | ||
|style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]] | | style="background-color:#fee0d2" | [[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]] | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]] | | style="background-color:#fee0d2" | [[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]] | ||
|style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]] | | style="background-color:#fee0d2" | [[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]] | ||
|style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]] | | style="background-color:#fee0d2" | [[Transformed lymphoma|Transformed lymphoma (TL)]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#fc9272" colspan="4" | '''Indolent lymphomas''' | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Chronic lymphocytic leukemia| Chronic lymphocytic leukemia (CLL/SLL)]] | | style="background-color:#fee0d2" | [[Chronic lymphocytic leukemia| Chronic lymphocytic leukemia (CLL/SLL)]] | ||
|style="background-color:#fee0d2"|[[Follicular lymphoma|Follicular lymphoma (FL)]] | | style="background-color:#fee0d2" | [[Follicular lymphoma|Follicular lymphoma (FL)]] | ||
|style="background-color:#fee0d2"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]] | | style="background-color:#fee0d2" | [[Hairy cell leukemia|Hairy cell leukemia (HCL)]] | ||
|style="background-color:#fee0d2"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]] | | style="background-color:#fee0d2" | [[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]] | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Indolent lymphoma|Indolent lymphoma (iNHL)]] | | style="background-color:#fee0d2" | [[Indolent lymphoma|Indolent lymphoma (iNHL)]] | ||
|style="background-color:#fee0d2"|[[B-cell lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]] | | style="background-color:#fee0d2" | [[B-cell lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]] | ||
|style="background-color:#fee0d2"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]] | | style="background-color:#fee0d2" | [[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]] | ||
|style="background-color:#fee0d2"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]] | | style="background-color:#fee0d2" | [[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#fc9272" colspan="4" | '''Plasma cell dyscrasias''' | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]] | | style="background-color:#fee0d2" | [[Light-chain (AL) amyloidosis]] | ||
|style="background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (main page)]] | | style="background-color:#fee0d2" | [[Multiple myeloma|Multiple myeloma (main page)]] | ||
|style="background-color:#fee0d2"|[[Multiple_myeloma,_induction|MM,]] induction | | style="background-color:#fee0d2" | [[Multiple_myeloma,_induction|MM,]] induction | ||
|style="background-color:#fee0d2"|[[Multiple_myeloma,_consolidation_and_maintenance|MM, consolidation &]] maintenance | | style="background-color:#fee0d2" | [[Multiple_myeloma,_consolidation_and_maintenance|MM, consolidation &]] maintenance | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Multiple_myeloma,_relapsed-refractory|MM, relapsed/refractory]] | | style="background-color:#fee0d2" | [[Multiple_myeloma,_relapsed-refractory|MM, relapsed/refractory]] | ||
|style="background-color:#fee0d2"|[[Plasma cell leukemia|Plasma cell leukemia (PCL)]] | | style="background-color:#fee0d2" | [[Plasma cell leukemia|Plasma cell leukemia (PCL)]] | ||
|style="background-color:#fee0d2"|[[POEMS syndrome]] | | style="background-color:#fee0d2" | [[POEMS syndrome]] | ||
|style="background-color:#fee0d2"|[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]] | | style="background-color:#fee0d2" | [[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#fc9272" colspan="4" | '''T-cell and NK-cell neoplasms''' | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]] | | style="background-color:#fee0d2" | [[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]] | ||
|style="background-color:#fee0d2"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]] | | style="background-color:#fee0d2" | [[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]] | ||
|style="background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]] | | style="background-color:#fee0d2" | [[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]] | ||
|style="background-color:#fee0d2"|[[Extranodal NK- and T-cell lymphoma, nasal type|Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT]] | | style="background-color:#fee0d2" | [[Extranodal NK- and T-cell lymphoma, nasal type|Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT]] | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]] | | style="background-color:#fee0d2" | [[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]] | ||
|style="background-color:#fee0d2"|[[NK- and T-cell lymphoma|NK- and T-cell lymphoma (NKTCL)]] | | style="background-color:#fee0d2" | [[NK- and T-cell lymphoma|NK- and T-cell lymphoma (NKTCL)]] | ||
|style="background-color:#fee0d2"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]] | | style="background-color:#fee0d2" | [[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]] | ||
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic lymphoma (T-LBL)]] | | style="background-color:#fee0d2" | [[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic lymphoma (T-LBL)]] | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[T-cell prolymphocytic leukemia | T-cell prolymphocytic lymphoma (T-PLL)]] | | style="background-color:#fee0d2" | [[T-cell prolymphocytic leukemia | T-cell prolymphocytic lymphoma (T-PLL)]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#fc9272" colspan="4" | '''Lymphoproliferative disorders''' | ||
|- | |- | ||
| | | style="background-color:#fee0d2" colspan="2" | [[Castleman disease]] | ||
| | | style="background-color:#fee0d2" colspan="2" | [[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#fc9272" colspan="4" | '''Histiocytic disorders''' | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]] | | style="background-color:#fee0d2" | [[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]] | ||
|style="background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]] | | style="background-color:#fee0d2" | [[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]] | ||
|style="background-color:#fee0d2"|[[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]] | | style="background-color:#fee0d2" | [[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]] | ||
|style="background-color:#fee0d2"|[[Rosai-Dorfman-Destombes disease]] | | style="background-color:#fee0d2" | [[Rosai-Dorfman-Destombes disease]] | ||
|- | |- | ||
|} | |} | ||
<span id="peds"></span> | <span id="peds"></span> | ||
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | {| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | ||
! | ! style="color:white; font-size:150%; background-color:#ba871a" colspan="4" align="center" | '''Pediatric Neoplasms''' | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#d1af67" colspan="4" | '''Pediatric CNS malignancies''' | ||
|- | |- | ||
|style="width: 25%; background-color:#e8d7b3"|[[Low-grade glioma, pediatric|Low-grade glioma]] | | style="width: 25%; background-color:#e8d7b3" | [[Low-grade glioma, pediatric|Low-grade glioma]] | ||
|style="width: 25%; background-color:#e8d7b3"|[[High-grade glioma, pediatric|High-grade glioma]] | | style="width: 25%; background-color:#e8d7b3" | [[High-grade glioma, pediatric|High-grade glioma]] | ||
|style="width: 25%; background-color:#e8d7b3"|[[Medulloblastoma]] | | style="width: 25%; background-color:#e8d7b3" | [[Medulloblastoma]] | ||
|style="width: 25%; background-color:#e8d7b3"| | | style="width: 25%; background-color:#e8d7b3" | | ||
|- | <br> | ||
| | |- | ||
|- | | style="font-size:125%; background-color:#d1af67" colspan="4" | '''Pediatric hematologic neoplasms''' | ||
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric | B-cell acute lymphoblastic leukemia (B-ALL)]] | |- | ||
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric, Ph-positive | B-ALL, Ph+]] | | style="background-color:#e8d7b3" | [[B-cell acute lymphoblastic leukemia, pediatric | B-cell acute lymphoblastic leukemia (B-ALL)]] | ||
|style="background-color:#e8d7b3"|[[T-cell acute lymphoblastic leukemia, pediatric | T-cell acute lymphoblastic leukemia (T-ALL)]] | | style="background-color:#e8d7b3" | [[B-cell acute lymphoblastic leukemia, pediatric, Ph-positive | B-ALL, Ph+]] | ||
|style="background-color:#e8d7b3"|[[Acute myeloid leukemia, pediatric | Acute myeloid leukemia (AML)]] | | style="background-color:#e8d7b3" | [[T-cell acute lymphoblastic leukemia, pediatric | T-cell acute lymphoblastic leukemia (T-ALL)]] | ||
|- | | style="background-color:#e8d7b3" | [[Acute myeloid leukemia, pediatric | Acute myeloid leukemia (AML)]] | ||
|style="background-color:#e8d7b3"|[[Anaplastic large cell lymphoma, pediatric | Anaplastic large cell lymphoma (ALCL)]] | |- | ||
|style="background-color:#e8d7b3"|[[Chronic myeloid leukemia, pediatric | Chronic myeloid leukemia (CML)]] | | style="background-color:#e8d7b3" | [[Anaplastic large cell lymphoma, pediatric | Anaplastic large cell lymphoma (ALCL)]] | ||
|style="background-color:#e8d7b3"|[[Juvenile myelomonocytic leukemia | Juvenile myelomonocytic leukemia (JMML)]] | | style="background-color:#e8d7b3" | [[Chronic myeloid leukemia, pediatric | Chronic myeloid leukemia (CML)]] | ||
|- | | style="background-color:#e8d7b3" | [[Juvenile myelomonocytic leukemia | Juvenile myelomonocytic leukemia (JMML)]] | ||
|style="background-color:#e8d7b3"|[[Classical Hodgkin lymphoma, pediatric |Classical Hodgkin lymphoma (cHL)]] | |- | ||
|style="background-color:#e8d7b3"|[[Non-Hodgkin lymphoma, pediatric | Non-Hodgkin lymphoma (NHL)]] | | style="background-color:#e8d7b3" | [[Classical Hodgkin lymphoma, pediatric |Classical Hodgkin lymphoma (cHL)]] | ||
|- | | style="background-color:#e8d7b3" | [[Non-Hodgkin lymphoma, pediatric | Non-Hodgkin lymphoma (NHL)]] | ||
| | |- | ||
|- | | style="font-size:125%; background-color:#d1af67" colspan="4" | '''Pediatric solid tumors''' | ||
|style="background-color:#e8d7b3"|[[Epithelioid sarcoma]] | |- | ||
|style="background-color:#e8d7b3"|[[Ewing sarcoma, pediatric|Ewing sarcoma]] | | style="background-color:#e8d7b3" | [[Epithelioid sarcoma]] | ||
|style="background-color:#e8d7b3"|[[Hepatoblastoma]] | | style="background-color:#e8d7b3" | [[Ewing sarcoma, pediatric|Ewing sarcoma]] | ||
|style="background-color:#e8d7b3"|[[Neuroblastoma]] | | style="background-color:#e8d7b3" | [[Hepatoblastoma]] | ||
|- | | style="background-color:#e8d7b3" | [[Neuroblastoma]] | ||
|style="background-color:#e8d7b3"|[[Osteosarcoma, pediatric|Osteosarcoma]] | |- | ||
|style="background-color:#e8d7b3"|[[Retinoblastoma]] | | style="background-color:#e8d7b3" | [[Osteosarcoma, pediatric|Osteosarcoma]] | ||
|style="background-color:#e8d7b3"|[[Rhabdomyosarcoma, pediatric|Rhabdomyosarcoma]] | | style="background-color:#e8d7b3" | [[Retinoblastoma]] | ||
|style="background-color:#e8d7b3"|[[Wilms tumor]] | | style="background-color:#e8d7b3" | [[Rhabdomyosarcoma, pediatric|Rhabdomyosarcoma]] | ||
|- | | style="background-color:#e8d7b3" | [[Wilms tumor]] | ||
|- | |||
|} | |} | ||
<span id="transplant"></span> | <span id="transplant"></span> | ||
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | {| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | ||
! | ! style="color:white; font-size:150%; background-color:#4a1486" colspan="4" align="center" | '''Transplant and Immune Effector Cells (IECs)''' | ||
|- | |- | ||
|style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]] | | style="width: 25%; background-color:#efedf5" | [[Stem cell mobilization]] | ||
|style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT]] | | style="width: 25%; background-color:#efedf5" | [[Allogeneic HSCT]] | ||
|style="width: 25%; background-color:#efedf5"|[[Autologous HSCT]] | | style="width: 25%; background-color:#efedf5" | [[Autologous HSCT]] | ||
|style="width: 25%; background-color:#efedf5"|[[Chimeric antigen receptor T cells (CAR-T)]] | | style="width: 25%; background-color:#efedf5" | [[Chimeric antigen receptor T cells (CAR-T)]] | ||
|- | |- | ||
|style="background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]] | | style="background-color:#efedf5" | [[Graft versus host disease|Graft versus host disease (GVHD)]] | ||
|style="background-color:#efedf5"|[[Hepatic veno-occlusive disease|Hepatic veno-occlusive disease (VOD/SOS)]] | | style="background-color:#efedf5" | [[Hepatic veno-occlusive disease|Hepatic veno-occlusive disease (VOD/SOS)]] | ||
|- | |- | ||
|} | |} | ||
<span id="classicalheme"></span> | <span id="classicalheme"></span> | ||
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | {| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | ||
| | | style="color:white; font-size:150%; background-color:#31a354" colspan="4" align="center" | '''Classical Hematology''' | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#a1d99b" colspan="4" | '''Hemostasis and thrombosis''' | ||
|- | |- | ||
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]] | | style="width: 25%; background-color:#e5f5e0" | [[Acquired coagulopathy]] | ||
|style="width: 25%; background-color:#e5f5e0"|[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]] | | style="width: 25%; background-color:#e5f5e0" | [[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]] | ||
|style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]] | | style="width: 25%; background-color:#e5f5e0" | [[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]] | ||
|style="width: 25%; background-color:#e5f5e0"|[[Congenital thrombotic thrombocytopenic purpura|Congenital thrombotic thrombocytopenic purpura (cTTP)]] | | style="width: 25%; background-color:#e5f5e0" | [[Congenital thrombotic thrombocytopenic purpura|Congenital thrombotic thrombocytopenic purpura (cTTP)]] | ||
|- | |- | ||
|style="width: 25%; background-color:#e5f5e0"|[[Hemophilia A]] | | style="width: 25%; background-color:#e5f5e0" | [[Hemophilia A]] | ||
|style="width: 25%; background-color:#e5f5e0"|[[Hemophilia B]] | | style="width: 25%; background-color:#e5f5e0" | [[Hemophilia B]] | ||
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]] | | style="width: 25%; background-color:#e5f5e0" | [[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]] | ||
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]] | | style="width: 25%; background-color:#e5f5e0" | [[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]] | ||
|- | |- | ||
|style="background-color:#e5f5e0"|[[Inherited thrombophilia]] | | style="background-color:#e5f5e0" | [[Inherited thrombophilia]] | ||
|style="background-color:#e5f5e0"|[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]] | | style="background-color:#e5f5e0" | [[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]] | ||
|style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]] | | style="background-color:#e5f5e0" | [[Venous thromboembolism|Venous thromboembolism (VTE)]] | ||
|style="background-color:#e5f5e0"|[[Von Willebrand disease|von Willebrand disease (vWD)]] | | style="background-color:#e5f5e0" | [[Von Willebrand disease|von Willebrand disease (vWD)]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#a1d99b" colspan="4" | '''Cytopenias''' | ||
|- | |- | ||
|style="background-color:#e5f5e0"|[[Aplastic anemia]] | | style="background-color:#e5f5e0" | [[Aplastic anemia]] | ||
|style="background-color:#e5f5e0"|[[Autoimmune cytopenia]] | | style="background-color:#e5f5e0" | [[Autoimmune cytopenia]] | ||
|style="background-color:#e5f5e0"|[[Immune thrombocytopenia|Immune thrombocytopenia (ITP)]] | | style="background-color:#e5f5e0" | [[Immune thrombocytopenia|Immune thrombocytopenia (ITP)]] | ||
|style="background-color:#e5f5e0"|[[Thrombocytopenia in liver disease]] | | style="background-color:#e5f5e0" | [[Thrombocytopenia in liver disease]] | ||
|- | |- | ||
|style="background-color:#e5f5e0"|[[WHIM syndrome]] | | style="background-color:#e5f5e0" | [[WHIM syndrome]] | ||
|- | |- | ||
| | | style="font-size:125%; background-color:#a1d99b" colspan="4" | '''Hemolytic disorders and Hemoglobinopathies''' | ||
|- | |- | ||
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]] | | style="background-color:#e5f5e0" | [[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]] | ||
|style="background-color:#e5f5e0"|[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]] | | style="background-color:#e5f5e0" | [[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]] | ||
|style="background-color:#e5f5e0"|[[Cold agglutinin disease|Cold agglutinin disease (CAD)]] | | style="background-color:#e5f5e0" | [[Cold agglutinin disease|Cold agglutinin disease (CAD)]] | ||
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]] | | style="background-color:#e5f5e0" | [[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]] | ||
|- | |- | ||
|style="background-color:#e5f5e0"|[[Pyruvate kinase deficiency|Pyruvate kinase deficiency (PKD)]] | | style="background-color:#e5f5e0" | [[Pyruvate kinase deficiency|Pyruvate kinase deficiency (PKD)]] | ||
|style="background-color:#e5f5e0"|[[Beta thalassemia]] | | style="background-color:#e5f5e0" | [[Beta thalassemia]] | ||
|style="background-color:#e5f5e0"|[[Sickle cell disease|Sickle cell disease (SCD)]] | | style="background-color:#e5f5e0" | [[Sickle cell disease|Sickle cell disease (SCD)]] | ||
|- | |- | ||
|} | |} | ||
<div style="text-align:center"><big>'''[[Special:AllPages|Browse our complete index of pages]]'''</big></div> | <div style="text-align:center"><big>'''[[Special:AllPages|Browse our complete index of pages]]'''</big></div> | ||
==Additional Information== | == Additional Information == | ||
== What We Do == | |||
<p>In the fast-moving field of oncology, keeping up with the latest data is a challenge. Neoplasm.org serves as a "living textbook" where:</p> | |||
*<p>'''Clinical Trial Results''' are summarized and categorized for quick reference.</p> | |||
*<p>'''Treatment Regimens''' are detailed with evidence-backed citations and toxicity profiles.</p> | |||
*<p>'''Collaborative Note-taking''' allows experts to contribute clinical pearls and real-world experience.</p> | |||
< | |||
*''' | |||
*''' | |||
*''' | |||
< | |||
== Why Neoplasm.org? == | |||
<p>Unlike static journals, our platform is built for speed and collaboration. Using modern collaborative tools (powered by Docmost), we allow credentialed contributors to update notes in real-time as new data emerges from ASCO, ESMO, and major journals.</p> | |||
*<p>'''Free to the Public''': Information that saves lives should not be behind a paywall.</p> | |||
*<p>'''Clinically Structured''': Organized by disease site, histology, and stage for maximum utility during rounds or tumor boards.</p> | |||
*<p>'''Evidence-Based''': Every note is rooted in published clinical evidence.</p> | |||
== Join the Collaboration == | |||
<p>Neoplasm.org is built by the oncology community, for the oncology community. Whether you are adding a new regimen or refining a trial summary, your contributions help build a more transparent and informed world for cancer care.</p><p>''Disclaimer: Neoplasm.org is an educational and research resource. Clinical decisions should always be made by a qualified healthcare professional.''</p> | |||
</ | |||
Revision as of 20:43, 27 December 2025
<span class="mwt-editable mwt-comment" id="R1766923378676" " draggable="false" contenteditable="true">Hides title of Main Page
Welcome to Neoplasm.org
Neoplasm.org is a collaborative, open-access knowledge base dedicated to the rapid dissemination of oncology clinical trial results and evidence-based treatment regimens.
Modeled after the collaborative spirit of the medical community, our mission is to translate complex research into actionable clinical insights—free of charge and accessible to everyone, from oncologists and researchers to students and patients.
| Guidelines | Solid Tumors |
| Pediatric Neoplasms | |||
|---|---|---|---|
| Pediatric CNS malignancies | |||
| Low-grade glioma | High-grade glioma | Medulloblastoma |
|
| Pediatric hematologic neoplasms | |||
| B-cell acute lymphoblastic leukemia (B-ALL) | B-ALL, Ph+ | T-cell acute lymphoblastic leukemia (T-ALL) | Acute myeloid leukemia (AML) |
| Anaplastic large cell lymphoma (ALCL) | Chronic myeloid leukemia (CML) | Juvenile myelomonocytic leukemia (JMML) | |
| Classical Hodgkin lymphoma (cHL) | Non-Hodgkin lymphoma (NHL) | ||
| Pediatric solid tumors | |||
| Epithelioid sarcoma | Ewing sarcoma | Hepatoblastoma | Neuroblastoma |
| Osteosarcoma | Retinoblastoma | Rhabdomyosarcoma | Wilms tumor |
| Transplant and Immune Effector Cells (IECs) | |||
|---|---|---|---|
| Stem cell mobilization | Allogeneic HSCT | Autologous HSCT | Chimeric antigen receptor T cells (CAR-T) |
| Graft versus host disease (GVHD) | Hepatic veno-occlusive disease (VOD/SOS) | ||
Additional Information
What We Do
In the fast-moving field of oncology, keeping up with the latest data is a challenge. Neoplasm.org serves as a "living textbook" where:
Clinical Trial Results are summarized and categorized for quick reference.
Treatment Regimens are detailed with evidence-backed citations and toxicity profiles.
Collaborative Note-taking allows experts to contribute clinical pearls and real-world experience.
Why Neoplasm.org?
Unlike static journals, our platform is built for speed and collaboration. Using modern collaborative tools (powered by Docmost), we allow credentialed contributors to update notes in real-time as new data emerges from ASCO, ESMO, and major journals.
Free to the Public: Information that saves lives should not be behind a paywall.
Clinically Structured: Organized by disease site, histology, and stage for maximum utility during rounds or tumor boards.
Evidence-Based: Every note is rooted in published clinical evidence.
Join the Collaboration
Neoplasm.org is built by the oncology community, for the oncology community. Whether you are adding a new regimen or refining a trial summary, your contributions help build a more transparent and informed world for cancer care.
Disclaimer: Neoplasm.org is an educational and research resource. Clinical decisions should always be made by a qualified healthcare professional.